Harmony Biosciences Holdings, Inc. (HRMY) Insider Trading

Last 12 months

Insiders sold $5.95M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Aug 2020.

Net open-market

−$5.95M

0 buys · 7 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

Aug 2020

Aug 26, 2020

Get an email when HRMY's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 16 – 18	Kumar Budur CHIEF MEDICAL OFFICER	Sold10b5-1 plan 3 parts	38,452	$43.05 average	$1.66M	75%	Form 4
Sep 4 – 8	Kumar Budur CHIEF MEDICAL OFFICER	Sold10b5-1 plan 4 parts	33,954	$42.80 average	$1.45M	72%	Form 4
Jan 26	Sandip Kapadia CHIEF FINANCIAL OFFICER	Sold10b5-1 plan	3,746	$37.15	$139k	13%	Form 4
Jan 15	Sandip Kapadia CHIEF FINANCIAL OFFICER	Sold10b5-1 plan	20,961	$35.92	$753k	100%	Form 4
Dec 12, 2025	Jeffrey M. Dayno PRESIDENT, CEO	Sold10b5-1 plan 2 parts	25,933	$40.11 average	$1.04M	100%	Form 4
Dec 5, 2025	Sandip Kapadia CHIEF FINANCIAL OFFICER	Sold10b5-1 plan	20,000	$39.54	$791k	100%	Form 4
Nov 21, 2025	Sandip Kapadia CHIEF FINANCIAL OFFICER	Sold10b5-1 plan	3,427	$35.00	$120k	100%	Form 4
Aug 15, 2025	Sandip Kapadia CHIEF FINANCIAL OFFICER	Sold10b5-1 plan	21,573	$36.50	$787k	100%	Form 4
Apr 1, 2025	Sandip Kapadia CHIEF FINANCIAL OFFICER	Sold10b5-1 plan 2 parts	6,987	$32.55 average	$227k	100%	Form 4
Mar 3, 2025	Jeffrey Dierks CHIEF COMMERCIAL OFFICER	Sold10b5-1 plan 2 parts	4,869	$32.67 average	$159k	100%	Form 4
Jan 24, 2025 – Jan 27, 2025	Jeffrey Dierks CHIEF COMMERCIAL OFFICER	Sold10b5-1 plan 3 parts	14,754	$37.38 average	$552k	100%	Form 4
Jan 27, 2025	Sandip Kapadia CHIEF FINANCIAL OFFICER	Sold10b5-1 plan	1,775	$38.05	$68k	100%	Form 4
Jan 21, 2025	Jeffrey M. Dayno PRESIDENT, CEO	Sold10b5-1 plan	19,293	$40.13	$774k	100%	Form 4
Jan 21, 2025	Sandip Kapadia CHIEF FINANCIAL OFFICER	Sold10b5-1 plan	25,000	$40.18	$1M	100%	Form 4
Jan 16, 2025 – Jan 21, 2025	Jeffrey Dierks CHIEF COMMERCIAL OFFICER	Sold10b5-1 plan 2 parts	30,598	$37.51 average	$1.15M	100%	Form 4
Jan 15, 2025	Jeffrey Dierks CHIEF COMMERCIAL OFFICER	Sold10b5-1 plan	10,507	$37.01	$389k	100%	Form 4
Jan 13, 2025	Jeffrey Dierks CHIEF COMMERCIAL OFFICER	Sold10b5-1 plan	7,180	$37.04	$266k	100%	Form 4
Nov 1, 2024 – Nov 5, 2024	Valor Equity Partners Iv-B L.p. Large holder	SoldNo plan 2 parts	4,600,000	$30.30 average	$139M	41%	Form 4
Nov 1, 2024 – Nov 5, 2024	Marshman Fund Trust II Large holder	SoldNo plan 2 parts	4,600,000	$30.30 average	$139M	43%	Form 4
Oct 29, 2024	Jeffrey Dierks CHIEF COMMERCIAL OFFICER	Sold10b5-1 plan	21,496	$40.47	$870k	100%	Form 4

Sep 16 – 1810b5-1 plan
Kumar Budur
CHIEF MEDICAL OFFICER · sold 38,452 at avg $43.05
$1.66M
75% of stake
Sep 4 – 810b5-1 plan
Kumar Budur
CHIEF MEDICAL OFFICER · sold 33,954 at avg $42.80
$1.45M
72% of stake
Jan 2610b5-1 plan
Sandip Kapadia
CHIEF FINANCIAL OFFICER · sold 3,746 at $37.15
$139k
13% of stake
Jan 1510b5-1 plan
Sandip Kapadia
CHIEF FINANCIAL OFFICER · sold 20,961 at $35.92
$753k
100% of stake
Dec 12, 202510b5-1 plan
Jeffrey M. Dayno
PRESIDENT, CEO · sold 25,933 at avg $40.11
$1.04M
100% of stake
Dec 5, 202510b5-1 plan
Sandip Kapadia
CHIEF FINANCIAL OFFICER · sold 20,000 at $39.54
$791k
100% of stake
Nov 21, 202510b5-1 plan
Sandip Kapadia
CHIEF FINANCIAL OFFICER · sold 3,427 at $35.00
$120k
100% of stake
Aug 15, 202510b5-1 plan
Sandip Kapadia
CHIEF FINANCIAL OFFICER · sold 21,573 at $36.50
$787k
100% of stake
Apr 1, 202510b5-1 plan
Sandip Kapadia
CHIEF FINANCIAL OFFICER · sold 6,987 at avg $32.55
$227k
100% of stake
Mar 3, 202510b5-1 plan
Jeffrey Dierks
CHIEF COMMERCIAL OFFICER · sold 4,869 at avg $32.67
$159k
100% of stake
Jan 24, 2025 – Jan 27, 202510b5-1 plan
Jeffrey Dierks
CHIEF COMMERCIAL OFFICER · sold 14,754 at avg $37.38
$552k
100% of stake
Jan 27, 202510b5-1 plan
Sandip Kapadia
CHIEF FINANCIAL OFFICER · sold 1,775 at $38.05
$68k
100% of stake
Jan 21, 202510b5-1 plan
Jeffrey M. Dayno
PRESIDENT, CEO · sold 19,293 at $40.13
$774k
100% of stake
Jan 21, 202510b5-1 plan
Sandip Kapadia
CHIEF FINANCIAL OFFICER · sold 25,000 at $40.18
$1M
100% of stake
Jan 16, 2025 – Jan 21, 202510b5-1 plan
Jeffrey Dierks
CHIEF COMMERCIAL OFFICER · sold 30,598 at avg $37.51
$1.15M
100% of stake
Jan 15, 202510b5-1 plan
Jeffrey Dierks
CHIEF COMMERCIAL OFFICER · sold 10,507 at $37.01
$389k
100% of stake
Jan 13, 202510b5-1 plan
Jeffrey Dierks
CHIEF COMMERCIAL OFFICER · sold 7,180 at $37.04
$266k
100% of stake
Nov 1, 2024 – Nov 5, 2024No plan
Valor Equity Partners Iv-B L.p.
Large holder · sold 4,600,000 at avg $30.30
$139M
41% of stake
Nov 1, 2024 – Nov 5, 2024No plan
Marshman Fund Trust II
Large holder · sold 4,600,000 at avg $30.30
$139M
43% of stake
Oct 29, 202410b5-1 plan
Jeffrey Dierks
CHIEF COMMERCIAL OFFICER · sold 21,496 at $40.47
$870k
100% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch HRMY, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

ANIPAni Pharmaceuticals Inc.

PTCTPTC Therapeutics, Inc.

IONSIonis Pharmaceuticals, Inc.

PBHPrestige Consumer Healthcare Inc.

CORTCorcept Therapeutics Incorporated

SUPNSupernus Pharmaceuticals Inc.

ACADAcadia Pharmaceuticals Inc.

INSMInsmed Inc.

Spot a number that looks wrong? Check it in HRMY's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing HRMY

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.